UY38592A - Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada, proceso para su preparación y composiciones farmacéuticas que las contienen - Google Patents

Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada, proceso para su preparación y composiciones farmacéuticas que las contienen

Info

Publication number
UY38592A
UY38592A UY0001038592A UY38592A UY38592A UY 38592 A UY38592 A UY 38592A UY 0001038592 A UY0001038592 A UY 0001038592A UY 38592 A UY38592 A UY 38592A UY 38592 A UY38592 A UY 38592A
Authority
UY
Uruguay
Prior art keywords
trifluorometil
crystalline form
dihydroisoquinolin
carboxamide
pyridin
Prior art date
Application number
UY0001038592A
Other languages
English (en)
Inventor
Carina Leys
Kristof Leonard Kimpe
Robert Michael Geertman
Haojuan Wei
Peng Zhou
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY38592A publication Critical patent/UY38592A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulga una forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-N-[2-(trifluorometil)piridin-4-il]-1H-pirazol-4-carboxamida (Compuesto A) monohidratada y a procesos para la preparación de esta. La forma cristalina y las composiciones de esta son útiles en el tratamiento de las enfermedades relacionadas con MALT-1.
UY0001038592A 2019-02-22 2020-02-21 Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada, proceso para su preparación y composiciones farmacéuticas que las contienen UY38592A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019075834 2019-02-22

Publications (1)

Publication Number Publication Date
UY38592A true UY38592A (es) 2020-08-31

Family

ID=69723907

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038592A UY38592A (es) 2019-02-22 2020-02-21 Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada, proceso para su preparación y composiciones farmacéuticas que las contienen

Country Status (20)

Country Link
US (1) US20220127249A1 (es)
EP (1) EP3927696B1 (es)
JP (1) JP2022523368A (es)
KR (1) KR20210131371A (es)
CN (1) CN113474339A (es)
AU (1) AU2020226723A1 (es)
BR (1) BR112021016400A2 (es)
CA (1) CA3129623A1 (es)
EA (1) EA202192320A1 (es)
EC (1) ECSP21067828A (es)
ES (1) ES2966132T3 (es)
IL (1) IL285675A (es)
JO (1) JOP20210227A1 (es)
MA (1) MA55019A (es)
MX (1) MX2021010133A (es)
PE (1) PE20212067A1 (es)
SG (1) SG11202108909SA (es)
TW (1) TW202045495A (es)
UY (1) UY38592A (es)
WO (1) WO2020169736A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
MX2023002117A (es) 2020-08-21 2023-05-12 Janssen Pharmaceutica Nv Forma amorfa de un inhibidor de malt1 y formulaciones de este.
BR112023017689A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)
WO2022184716A1 (en) 2021-03-03 2022-09-09 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor
MX2024001840A (es) 2021-08-09 2024-02-28 Janssen Pharmaceutica Nv Composiciones para usar en el tratamiento de neoplasias de celulas b.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008012096A (es) * 2006-03-22 2008-12-17 Vertex Pharma Inhibidores de proteina cinasa c-met para el tratamiento de trastornos proliferativos.
WO2011036885A1 (ja) * 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
WO2013178591A1 (en) * 2012-05-31 2013-12-05 F. Hoffmann-La Roche Ag Aminoquinazoline and pyridopyrimidine derivatives
US10835524B2 (en) * 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
MX2023002117A (es) * 2020-08-21 2023-05-12 Janssen Pharmaceutica Nv Forma amorfa de un inhibidor de malt1 y formulaciones de este.

Also Published As

Publication number Publication date
WO2020169736A1 (en) 2020-08-27
EA202192320A1 (ru) 2021-11-16
KR20210131371A (ko) 2021-11-02
MA55019A (fr) 2021-12-29
SG11202108909SA (en) 2021-09-29
EP3927696C0 (en) 2023-10-18
US20220127249A1 (en) 2022-04-28
ES2966132T3 (es) 2024-04-18
ECSP21067828A (es) 2021-11-18
EP3927696A1 (en) 2021-12-29
TW202045495A (zh) 2020-12-16
PE20212067A1 (es) 2021-10-26
IL285675A (en) 2021-10-31
BR112021016400A2 (pt) 2021-10-13
EP3927696B1 (en) 2023-10-18
CN113474339A (zh) 2021-10-01
AU2020226723A1 (en) 2021-08-19
CA3129623A1 (en) 2020-08-27
JP2022523368A (ja) 2022-04-22
JOP20210227A1 (ar) 2023-01-30
MX2021010133A (es) 2021-09-23

Similar Documents

Publication Publication Date Title
UY38592A (es) Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada, proceso para su preparación y composiciones farmacéuticas que las contienen
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
PE20211810A1 (es) Compuestos novedosos
JOP20190182B1 (ar) أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga
CL2018001145A1 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
PE20180160A1 (es) Sulfonilureas y compuestos relacionados y uso de estos
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
PE20161170A1 (es) Composiciones farmaceuticas que comprenden azd9291
AR111469A1 (es) Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
CO2021008816A2 (es) Moduladores de trex1
CY1124523T1 (el) Ν-[5-(αμινοσουλφονυλο)-4-μεθυλ-1,3-θειαζολ-2-υλ]-ν-μεθυλ-2-[4-(2-πυριδινυλ)-φαινυλ]-ημιενυδρη ελευθερη βαση ακεταμιδιου, μεθοδοι κατασκευης και χρησεις αυτης
CL2018001830A1 (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
MX2023009388A (es) Metodos para tratar alteraciones del comportamiento.
JOP20210338A1 (ar) نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد
AR108712A1 (es) (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis
CL2022001172A1 (es) Forma amorfa de un receptor del componente c5a del complemento
CL2012000611A1 (es) Compuesto 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2- trifluoro-etoxi)-nicotinamida, util como agente que aumenta el colesterol hdl; proceso de obtencion del compuesto; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la aterosclerosis, dislipidemia, enfermedades cardiovasculares, entre otras.
CL2023000534A1 (es) Antagonista cristalino del receptor edg-2 y métodos de fabricación
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
EA201991570A1 (ru) Амидные соединения и их применение
AR110481A1 (es) MODULADORES DE ROR g (RORg)